{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:04:09Z","timestamp":1751954649535,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["218S809"],"award-info":[{"award-number":["218S809"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00284-022-02882-w","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T09:08:25Z","timestamp":1651914505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["hsa-miR-17-5p: A Possible Predictor of Ombitasvir\/Paritaprevir\/Ritonavir\u2009+\u2009Dasabuvir\u2009\u00b1\u2009Ribavirin Therapy Efficacy in Hepatitis C Infection"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-0556","authenticated-orcid":false,"given":"Zehra","family":"\u00d6ks\u00fcz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-5580","authenticated-orcid":false,"given":"Enver","family":"\u00dc\u00e7bilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-5509","authenticated-orcid":false,"given":"Mehmet Sami","family":"Serin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-7515","authenticated-orcid":false,"given":"Serkan","family":"Yara\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2835-6979","authenticated-orcid":false,"given":"G\u00fclhan \u00d6rekici","family":"Temel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-4716","authenticated-orcid":false,"given":"Orhan","family":"Sezgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"key":"2882_CR1","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342. https:\/\/doi.org\/10.1002\/hep.26141","journal-title":"Hepatology"},{"key":"2882_CR2","doi-asserted-by":"publisher","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z (2017) Hepatitis C virus infection. Nat Rev Dis Primers 3:17006. https:\/\/doi.org\/10.1038\/nrdp.2017.6","journal-title":"Nat Rev Dis Primers"},{"key":"2882_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1124\/dmd.117.079038","volume":"46","author":"KL Garrison","year":"2017","unstructured":"Garrison KL, German P, Mogalian E, Mathias A (2017) The drug-drug interaction potential of antiviral agents for the treatment of chronic Hepatitis C infection. Drug Metab Dispos 46:1212\u20131225. https:\/\/doi.org\/10.1124\/dmd.117.079038","journal-title":"Drug Metab Dispos"},{"key":"2882_CR4","unstructured":"Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets;dasabuvir tablets), co-packaged for oral use [package insert] (2014). AbbVie Inc, North Chicago"},{"key":"2882_CR5","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3748\/wjg.v22.i4.1421","volume":"4","author":"R Gonz\u00e1lez-Grande","year":"2016","unstructured":"Gonz\u00e1lez-Grande R, Jim\u00e9nez-P\u00e9rez M, Arjona CG, Torres JM (2016) New approaches in the treatment of hepatitis C. World J Gastroenterol 4:1421\u20131432. https:\/\/doi.org\/10.3748\/wjg.v22.i4.1421","journal-title":"World J Gastroenterol"},{"key":"2882_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"6","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ (2017) Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 6:1204\u20131212. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.025","journal-title":"J Hepatol"},{"key":"2882_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","volume":"3","author":"A Sangiovanni","year":"2020","unstructured":"Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L et al (2020) Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol 3:593\u2013602. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.030","journal-title":"J Hepatol"},{"key":"2882_CR8","doi-asserted-by":"publisher","first-page":"0168","DOI":"10.1016\/j.jhep.2017.08.030","volume":"5","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K (2017) HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 5:0168\u20138278. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030","journal-title":"J Hepatol"},{"key":"2882_CR9","doi-asserted-by":"publisher","first-page":"37487","DOI":"10.18632\/oncotarget.9303","volume":"25","author":"V De Re","year":"2016","unstructured":"De Re V, De Zorzi M, Caggiari L, Lauletta G, Tornesello ML, Fognani E et al (2016) HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget 25:37487\u201337497. https:\/\/doi.org\/10.18632\/oncotarget.9303","journal-title":"Oncotarget"},{"key":"2882_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/1471-2334-12-384","volume":"12","author":"Y Qi","year":"2012","unstructured":"Qi Y, Cui L, Ge Y, Shi Z, Zhao K, Guo X et al (2012) Altered serum microRNAs as biomarkers for theearly diagnosis of pulmonary tuberculosis infection. BMC Infect Dis 12:384. https:\/\/doi.org\/10.1186\/1471-2334-12-384","journal-title":"BMC Infect Dis"},{"key":"2882_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019494","volume":"7","author":"MI Qadir","year":"2017","unstructured":"Qadir MI, Faheem A (2017) miRNA: a diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr 7:197\u2013204. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2017019494","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2882_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.22749","volume":"49","author":"S Ura","year":"2009","unstructured":"Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R et al (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 49:1098\u20131111. https:\/\/doi.org\/10.1002\/hep.22749","journal-title":"Hepatology"},{"key":"2882_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11033-014-3819-9","volume":"3","author":"Z Oksuz","year":"2015","unstructured":"Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, Aslan G et al (2015) Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep 3:713\u2013720. https:\/\/doi.org\/10.1007\/s11033-014-3819-9","journal-title":"Mol Biol Rep"},{"key":"2882_CR14","doi-asserted-by":"publisher","first-page":"97078","DOI":"10.1371\/journal.pone.0097078","volume":"9","author":"A Tsubota","year":"2014","unstructured":"Tsubota A, Mogushi K, Aizaki H, Miyaguchi K, Nagatsuma K, Matsudaira H et al (2014) Involvement of MAP3K8 and miR-17-5p in poor virologic response to interferon-based combination therapy for chronic hepatitis C. PLoS ONE 9:97078. https:\/\/doi.org\/10.1371\/journal.pone.0097078","journal-title":"PLoS ONE"},{"issue":"10","key":"2882_CR15","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/ijc.33111","volume":"147","author":"S Ghosh","year":"2020","unstructured":"Ghosh S, Bhowmik S, Majumdar S, Goswami A, Chakraborty J, Gupta S, Aggarwal S, Ray S, Chatterjee R, Bhattacharyya S, Dutta M, Datta S, Chowdhury A, Dhali GK, Banerjee S (2020) The exosome encapsulated microRNAs as circulating diagnostic marker for hepatocellular carcinoma with low alpha-fetoprotein. Int J Cancer 147(10):2934\u20132947. https:\/\/doi.org\/10.1002\/ijc.33111","journal-title":"Int J Cancer"},{"key":"2882_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/cbf.3213","volume":"7","author":"X Dong","year":"2016","unstructured":"Dong X, Ding W, Ye J, Yan D, Xue F, Xu L, Yin J, Guo W (2016) MiR-24-3p enhances cell growth in hepatocellular carcinoma by targeting metallothionein 1M. Cell Biochem Funct 7:491\u2013496. https:\/\/doi.org\/10.1002\/cbf.3213","journal-title":"Cell Biochem Funct"},{"key":"2882_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/08941939.2011.618523(20)","volume":"25","author":"L Chen","year":"2012","unstructured":"Chen L, Jiang M, Yuan W, Tang H (2012) miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 25:156\u2013161. https:\/\/doi.org\/10.3109\/08941939.2011.618523(20)","journal-title":"J Invest Surg"},{"key":"2882_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ijc.26143","volume":"6","author":"HD Nischalke","year":"2012","unstructured":"Nischalke HD, Coenen M, Berger C, Aldenhoff K, M\u00fcller T, Berg T et al (2012) The toll-like receptor 2 (TLR2) -196 to -174 del\/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 6:1470\u20131475. https:\/\/doi.org\/10.1002\/ijc.26143","journal-title":"Int J Cancer"},{"key":"2882_CR19","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2004.08.067","volume":"127","author":"A Dolganiuc","year":"2014","unstructured":"Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G (2014) Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2- mediated pathways and inflammatory activation. Gastroenterology 127:1513\u20131524. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.067","journal-title":"Gastroenterology"},{"key":"2882_CR20","unstructured":"miScript\u00ae Microfluidics Handbook. Qiagen (2018) https:\/\/www.qiagen.com\/fi\/resources\/resourcedetail?id=04819b1f-a924-49ee-b7d5-49a3b5c52092&lang=en Accessed 10 March 2022"},{"key":"2882_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"6","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 6:1101. https:\/\/doi.org\/10.1038\/nprot.2008.73","journal-title":"Nat Protoc"},{"key":"2882_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00439-020-02136-4","volume":"139","author":"P Nahon","year":"2020","unstructured":"Nahon P, Cobat A (2020) Human genetics of HCV infection phenotypes in the era of direct-acting antivirals. Hum Genet 139:855\u2013863. https:\/\/doi.org\/10.1007\/s00439-020-02136-4","journal-title":"Hum Genet"},{"key":"2882_CR23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/hep.23566","volume":"5","author":"F Yang","year":"2010","unstructured":"Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y, Sun S (2010) miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology 5:1614\u20131623. https:\/\/doi.org\/10.1002\/hep.23566","journal-title":"Hepatology"},{"key":"2882_CR24","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3892\/etm.2017.5667","volume":"3","author":"L Wan","year":"2018","unstructured":"Wan L, Yuan X, Liu M, Xue B (2018) miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells. Exp Ther Med 3:2429\u20132435. https:\/\/doi.org\/10.3892\/etm.2017.5667","journal-title":"Exp Ther Med"},{"key":"2882_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ajpath.2015.10.003","volume":"2","author":"S Bhattacharya","year":"2016","unstructured":"Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Bisceglie AMD, Ray RB (2016) Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am J Pathol 2:242\u2013247. https:\/\/doi.org\/10.1016\/j.ajpath.2015.10.003","journal-title":"Am J Pathol"},{"key":"2882_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","volume":"4","author":"E Serti","year":"2017","unstructured":"Serti E, Park H, Keane M, O\u2019Keefe AC, Rivera E, Liang TJ et al (2017) Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN alpha. Gut 4:724\u2013735. https:\/\/doi.org\/10.1136\/gutjnl-2015-310033","journal-title":"Gut"},{"key":"2882_CR27","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdw219","volume":"8","author":"TC Wirth","year":"2016","unstructured":"Wirth TC, Manns MP (2016) The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 8:1467\u20131474. https:\/\/doi.org\/10.1093\/annonc\/mdw219","journal-title":"Ann Oncol"},{"key":"2882_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2008.04.003","volume":"135","author":"QW Wong","year":"2008","unstructured":"Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of stathmin1. Gastroenterology 135:257\u2013269. https:\/\/doi.org\/10.1053\/j.gastro.2008.04.003","journal-title":"Gastroenterology"},{"key":"2882_CR29","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/j.gastro.2004.08.067","volume":"127","author":"A Dolganiuc","year":"2004","unstructured":"Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G (2004) Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2- mediated pathways and inflammatory activation. Gastroenterology 127:1513\u20131524. https:\/\/doi.org\/10.1053\/j.gastro.2004.08.067","journal-title":"Gastroenterology"},{"key":"2882_CR30","first-page":"281","volume":"5","author":"EL Renner","year":"1992","unstructured":"Renner EL, D\u00e4llenbach A (1992) Increased liver enzymes: whatshould be done? TherUmsch 5:281\u2013286","journal-title":"TherUmsch"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-02882-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-022-02882-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-022-02882-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T18:13:56Z","timestamp":1652811236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-022-02882-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2882"],"URL":"https:\/\/doi.org\/10.1007\/s00284-022-02882-w","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"type":"print","value":"0343-8651"},{"type":"electronic","value":"1432-0991"}],"subject":[],"published":{"date-parts":[[2022,5,7]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Mersin University Clinical Research (approval number: 2017\/88). All patients gave signed informed consent for their blood to be used for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"An Informed consent had been taken from all participants of the study on a specifically designed proforma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The participants were informed about publishing the results and they all agreed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"186"}}